Hydroxypropyl-beta-cyclodextrin

DRUG3 trials

Sponsors

Cyclo Therapeutics, Inc.

Conditions

Niemann-Pick Disease, Type C1

Phase 1

Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients

CompletedNCT02912793

Cyclo Therapeutics, Inc.Niemann-Pick Disease, Type C1

Start: 2017-03-20End: 2021-03-03Updated: 2021-08-10

Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)

CompletedNCT02939547

Cyclo Therapeutics, Inc.Niemann-Pick Disease, Type C1

Start: 2017-10-11End: 2020-02-10Updated: 2021-02-21

Phase 3

Phase 3 Study to Evaluate Intravenous Trappsol(R) Cyclo(TM) in Pediatric and Adult Patients With Niemann-Pick Disease Type C1

Active, not recruitingNCT04860960

Cyclo Therapeutics, Inc.Niemann-Pick Disease, Type C1

Start: 2021-07-20End: 2026-06-30Updated: 2024-06-04

Related Papers

Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial.

2023-06-2912 citations

Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial

Molecular Genetics and Metabolism2022-10-1740 citations